Rapid responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on thebmj.com. Although a selection of rapid responses will be included online and in print as readers' letters, their first appearance online means that they are published articles. If you need the url (web address) of an individual response, perhaps for citation purposes, simply click on the response headline and copy the url from the browser window. Letters are indexed in PubMed.
As much as I abhor misleading marketing and the idea of alleged promotion of the off-label use of liraglutide in patients who did not have type 2 diabetes, I wonder if the BMJ is also guilty of making some misleading claims in the article in reporting that:
"sales of liraglutide, which totalled $843bn last year. "
While I acknowledge the currency of this quote was not stated, I am curious to know where the sales statistics of 840 billion dollars come from.
Afterall it wasn't long ago they were aspiring to hit annual global liraglutide sales of USD1bn.